Please assess the completion status of the following clinical trial:

Trial Title: Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Males or females~* type 1 diabetes~* a plan to shift from twice daily glargine or detemir to once daily degludec~* HbA1c \>=7.0%~* Informed consent~Exclusion Criteria:~* Age \<18 or \>65~* HbA1c \<7.0%~* Pregnancy or lactation~* Recent (within 3 months) acute diseases or surgery~* Cancer~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients shifting to insulin degludec (Type: None): Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
- Patients remaining on twice daily glargine/detemir (Type: None): Patients continuing on twice daily glargine or detemir

Based on this trial design, predict the completion outcome and termination type (if applicable).